Stay updated with breaking news from Entresto hfp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Cosentyx (+13% cc), Xiidra acquisition (+95% cc) Promacta/Revolade (+23% cc), Piqray (reaching USD 0.3 billion) Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc) COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retail Core operating income² grew 13% (cc, +9% USD) and Innovative Medicines and Sandoz core margin improved to 35% and 24% of sales respectively, driven by sales growth, lower spend and productivity Continued transformation of Manufacturing and Business Services contributing to core margin expansion ....